Charon, Lucie
Launois, Claire
Perotin, Jeanne-Marie
Ravoninjatovo, Bruno
Mulette, Pauline
Ancel, Julien
Guillard, Thomas
Muggeo, Anaëlle
Dormoy, Valérian
Griffon, Muriel
Carré, Sophie
Lebargy, François
Deslée, Gaëtan
Dury, Sandra
Funding for this research was provided by:
university hospital of reims
Université de Reims Champagne-Ardenne
Article History
Received: 12 June 2023
Accepted: 9 October 2023
First Online: 21 November 2023
Declarations
:
: The patients were prospectively recruited from the University Hospital of Reims - Department of Respiratory Diseases between November 2016 and December 2019. Patients were included in the RINNOPARI study (Recherche et INNOvation en PAthologie Respiratoire Inflammatoire). This study was approved by the Ethics Committee of Dijon EST I on 31rd October 2016(N°2016-A00242-49) and by the French National Agency for Medicines and Health Products (ANSM) on 25th April 2016. The protocol was registered on ClinicalTrials.gov (NCT02924818, first posted on 5th October 2016). Each patient signed a written informed consent form. All methods including recruitment, data collection and analysis have been performed in accordance with the declaration of Helsinki.
: Not applicable.
: Each patient signed a written informed consent.
: The authors declare no competing interests.